HPPH (Photochlor) is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.

Fluorescence image of 4T1 cells incubated with 0.49 µg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 µM HPPH and 0.49 µg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 µM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm²). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm² given)^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

636.82

C₃₉H₄₈N₄O₄

149402-51-7

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

DMSO : 125 mg/mL (196.29 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.5 mg/mL (3.93 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (3.93 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.5 mg/mL (3.93 mM); Suspended solution

  此方案可获得 ≥ 2.5 mg/mL (3.93 mM，饱和度未知) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90% corn oil

  Solubility: ≥ 2.5 mg/mL (3.93 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (3.93 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Rong P, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39.

  [2]. Shams M, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97.

4T1 cells are cultured in 96-well cell culture plates at 1×10⁴/well for 24 h and then treated with GO-PEG-HPPH, HPPH, or GO-PEG at a series of concentrations (0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 μM). Then, 20 µL of MTT solution (5.0 mg/mL) is added to each well. After the 4 h incubation with the MTT, the media are removed and 100 µL of DMSO is added to solubilize the formazan crystals. The cell toxicity efficacy is measured with a microplate reader at an absorbance of 570 nm^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Mice^[2]
Tumor-bearing mice are injected in the tail vein with 0.4 μmol/kg HPPH or 5 mg/kg Porfimer sodium (PII), followed 18-24 h later by illumination to a total light dose of 48 J/cm² or 132 J/cm² delivered at a light dose-rate of 14 mW/cm². Control mice are treated with photosensitizer or light alone. Mice receiving a combination PDT regimen are treated initially with 0.4 μmol/kg HPPH or 5 mg/kg PII followed 18-24 h later by light dose of 48 J/cm² given at 14 mW/cm²; 9 days later, mice are again injected with photosensitizer and tumors are illuminated with light at a dose of 132 J/cm² given at 14 mW/cm^2[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Rong P, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39.

  [2]. Shams M, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97.